Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox


Novel Cell Culture Derived Influenza Vaccines

The disadvantages of the conventional production methodology, including possible shortage of eggs in a pandemic situation, selection of egg-adapted variants have repeatedly emphasized the necessity for production of influenza vaccines on a well characterized and stable cell line.

The continuous monkey kidney cell line, known as Vero, has previously been accepted by regulatory authorities in Europe and the US for human vaccine products such as poliomyelitis and rabies vaccines. The excellent safety record of Vero cells used in the production of biologicals has been demonstrated by the consumption of more than one hundred million doses of the Vero cell derived polio vaccine over the last 18 years worldwide in nearly 60 countries.

Baxter’s influenza vaccine, currently in the late stage development, will be the first in the industry to be based on Vero cell continuous cell line. It is completely free from egg proteins, which minimizes the risk of allergic reactions, exposure to antibiotics, and free of the preservative thiomersal.

Today, this economic technology of influenza vaccine production represents the most modern and reliable way to maintain high quality standards of the product and to ensure sufficient quantities of vaccines in emergency situations.

 » Printversion

  » find


Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,